Cargando…

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

BACKGROUND: To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis. METHODS: A systematic review was undertaken to identify double-blind randomized controlled trials (RCTs). PubMed, Web of Science, Cochrane Library, EMBASE, and Google Scholar dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jing, Wang, Zongming, Zhang, Xilin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382754/ https://www.ncbi.nlm.nih.gov/pubmed/32724829 http://dx.doi.org/10.1155/2020/4975628

Ejemplares similares

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Guselkumab for plaque psoriasis
Publicado: (2019)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
por: Galluzzo, Marco, et al.
Publicado: (2020)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies
por: Fu, Hongyi, et al.
Publicado: (2022)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial
por: Blauvelt, A., et al.
Publicado: (2020)

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
por: Diels, J., et al.
Publicado: (2020)

Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
por: Zhu, Yaowei, et al.
Publicado: (2020)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
por: Blauvelt, A., et al.
Publicado: (2020)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
por: Hung, Yi-Teng, et al.
Publicado: (2021)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

A Case of the Safety and Efficacy of Guselkumab in Psoriasis with Alcoholic Liver Cirrhosis
por: Nam, Hyun Min, et al.
Publicado: (2021)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
por: Jung, Seung-Won, et al.
Publicado: (2022)

Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient
por: Kim, Sa Rang, et al.
Publicado: (2019)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2021)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
por: MÄLKÖNEN, Tarja, et al.
Publicado: (2022)

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Eczematous eruption after guselkumab treatment for psoriasis
por: Reyn, Birgit, et al.
Publicado: (2019)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2022)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
por: Umezawa, Yoshinori, et al.
Publicado: (2021)

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
por: Wang, Yuqian, et al.
Publicado: (2023)

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
por: Armstrong, April W., et al.
Publicado: (2018)

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis
por: Anil Kumar, Mysore S., et al.
Publicado: (2018)

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry
por: Hugo, Jan, et al.
Publicado: (2023)

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation
por: Herranz-Pinto, Pedro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_seghjvkq8r5qslumjma327c5rr